...
首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis
【24h】

Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis

机译:胆汁小管动力学的早期改变和Rho激酶/肌球蛋白轻链激酶途径是药物诱导的肝内胆汁淤积的特征。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Intrahepatic cholestasis represents 20%-40% of drug-induced injuries from which a large proportion remains unpredictable. We aimed to investigate mechanisms underlying drug-induced cholestasis and improve its early detection using human HepaRG cells and a set of 12 cholestatic drugs and six noncholestatic drugs. In this study, we analyzed bile canaliculi dynamics, Rho kinase (ROCK)/myosin light chain kinase (MLCK) pathway implication, efflux inhibition of taurocholate [a predominant bile salt export pump (BSEP) substrate], and expression of the major canalicular and basolateral bile acid transporters. We demonstrated that 12 cholestatic drugs classified on the basis of reported clinical findings caused disturbances of both bile canaliculi dynamics, characterized by either dilatation or constriction, and alteration of the ROCK/MLCK signaling pathway, whereas noncholestatic compounds, by contrast, had no effect. Cotreatment with ROCK inhibitor Y-27632 [4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride] and MLCK activator calmodulin reduced bile canaliculi constriction and dilatation, respectively, confirming the role of these pathways in drug-induced intrahepatic cholestasis. By contrast, inhibition of taurocholate efflux and/or human BSEP overexpressed in membrane vesicles was not observed with all cholestatic drugs; moreover, examples of noncholestatic compounds were reportedly found to inhibit BSEP. Transcripts levels of major bile acid transporters were determined after 24-hour treatment. BSEP, Na+-taurocholate cotransporting polypeptide, and organic anion transporting polypeptide B were downregulated with most cholestatic and some noncholestatic drugs, whereas deregulation of multidrug resistance-associated proteins was more variable, probably mainly reflecting secondary effects. Together, our results show that cholestatic drugs consistently cause an early alteration of bile canaliculi dynamics associated with modulation of ROCK/MLCK and these changes are more specific than efflux inhibition measurements alone as predictive nonclinical markers of drug-induced cholestasis.
机译:肝内胆汁淤积占药物性损伤的20%-40%,其中很大一部分仍是不可预测的。我们旨在研究药物诱发的胆汁淤积的潜在机制,并使用人类HepaRG细胞和一组12种胆汁抑制药物和6种非胆汁抑制药物改善其早期发现。在这项研究中,我们分析了胆小管动力学,Rho激酶(ROCK)/肌球蛋白轻链激酶(MLCK)通路的含义,牛磺胆酸盐[主要的胆汁盐输出泵(BSEP)底物]的外排抑制以及主要的小管和基底外侧胆汁酸转运蛋白。我们证明了根据报告的临床发现归类的12种胆汁郁积药物会引起胆管动态的紊乱,其特征是扩张或收缩,以及ROCK / MLCK信号通路的改变,而非胆汁郁郁的化合物则没有作用。 ROCK抑制剂Y-27632 [4-(1-氨基乙基)-N-(4-吡啶基)环己烷甲酰胺二盐酸盐]和MLCK激活剂钙调蛋白的共同治疗分别降低了胆管的收缩和扩张,证实了这些途径在药物诱导的肝内的作用胆汁淤积。相反,在所有胆汁抑制药物中均未观察到牛磺胆酸盐外排和/或人BSEP在膜囊泡中的过度表达。此外,据报道发现非胆汁抑制化合物可抑制BSEP。处理24小时后,确定主要胆汁酸转运蛋白的转录水平。 BSEP,Na +-牛磺胆酸盐共转运多肽和有机阴离子转运多肽B在大多数胆汁抑制药和一些非胆汁抑制药中均被下调,而与多药耐药性相关的蛋白质的失控则变化更大,可能主要反映了次级作用。总之,我们的结果表明,胆汁抑制药始终导致与ROCK / MLCK调节相关的胆小管动力学的早期改变,并且这些改变比作为药物诱导的胆汁淤积的预测性非临床指标的单独外排抑制测量更具特异性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号